Recent developments in early pregnancy screening: Are we getting closer to the Holy Grail?

Medical Journal of Australia

Volumn 200, Issue 3, 2014, Pages 140-141

  Kane, Stefan C ^a   da Silva Costa, Fabricio ^a   Brennecke, Shaun P ^b  

^a ROYAL WOMEN'S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANEUPLOIDY; FEMALE; HUMANS; MATERNAL SERUM SCREENING TESTS; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PREGNANCY, HIGH-RISK; PRENATAL DIAGNOSIS; RISK ASSESSMENT;

EID: 84894095031     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/mja13.10955     Document Type: Note

References (15)

1. North RA, McCowan LM, Dekker GA, et al. Clinical risk prediction for pre-eclampsia in nulliparous women: development of model in international prospective cohort. BMJ 2011; 342: d1875.
2. Nicolaides KH. Screening for fetal aneuploidies at 11 to 13 weeks. Prenat Diagn 2011; 31: 7-15.
3. O'Leary P, Breheny N, Reid G, et al. Regional variations in prenatal screening across Australia: stepping towards a national policy framework. Aust N Z J Obstet Gynaecol 2006; 46: 427-432.
4. Morain S, Greene MF, Mello MM. A new era in noninvasive prenatal testing. N Engl J Med 2013; 369: 499-501.
5. Yu SC, Jiang P, Choy KW, et al. Noninvasive prenatal molecular karyotyping from maternal plasma. PLOS ONE 2013; 8: e60968.
6. Hui L, Hyett J. Noninvasive prenatal testing for trisomy 21: challenges for implementation in Australia. Aust N Z J Obstet Gynaecol 2013; 53: 416-424.
7. Dugoff L, Hobbins JC, Malone FD, et al. First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial). Am J Obstet Gynecol 2004; 191: 1446-1451.
8. Poon LC, Kametas NA, Maiz N, et al. First-trimester prediction of hypertensive disorders in pregnancy. Hypertension 2009; 53: 812-818.
9. Park FJ, Leung CH, Poon LC, et al. Clinical evaluation of a first trimester algorithm predicting the risk of hypertensive disease of pregnancy. Aust N Z J Obstet Gynaecol 2013; 53: 532-539.
10. Schneuer FJ, Nassar N, Guilbert C, et al. First trimester screening of serum soluble fms-like tyrosine kinase-1 and placental growth factor predicting hypertensive disorders of pregnancy. Pregnancy Hypertens 2013; 3: 215-221.
11. Nicolaides KH. Turning the pyramid of prenatal care. Fetal Diagn Ther 2011; 29: 183-196.
12. Greco E, Gupta R, Syngelaki A, et al. First-trimester screening for spontaneous preterm delivery with maternal characteristics and cervical length. Fetal Diagn Ther 2012; 31: 154-161.
13. Nanda S, Savvidou M, Syngelaki A, et al. Prediction of gestational diabetes mellitus by maternal factors and biomarkers at 11 to 13 weeks. Prenat Diagn 2011; 31: 135-141.
14. Karagiannis G, Akolekar R, Sarquis R, et al. Prediction of small-for-gestation neonates from biophysical and biochemical markers at 11-13 weeks. Fetal Diagn Ther 2011; 29: 148-154.
15. Wilson JMG, Jungner G. Principles and practice of screening for disease. Public health papers no. 34. Geneva: World Health Organization, 1968. http://whqlibdoc.who.int/php/WHO_PHP_34.pdf (accessed Nov 2013).